ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
종양학 바이오시밀러 시장 규모는 최근 급성장하고 있습니다. 2025년 113억 5,000만 달러에서 2026년에는 128억 3,000만 달러에 이르고, CAGR 13.0%의 성장이 전망되고 있습니다. 지난 수년간의 성장에는 참조 생물학적 제제의 높은 비용, 암 바이오시밀러공급 제한, 전 세계 암 발병률 증가, 병원 및 약국 인프라 확충, 단일클론항체 바이오시밀러의 조기 규제 승인 등이 주요 요인으로 작용한 것으로 보입니다.
암치료용 바이오시밀러 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 212억 8,000만 달러에 이르고, CAGR은 13.5%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 펨브롤리주맙과 페그필그라스팀을 포함한 새로운 바이오시밀러 의약품 출시, 온라인 약국 유통 채널 확대, 면역조절제 및 조혈제 채택 증가, 암 치료 접근성 향상을 위한 정부 정책 강화, 개인 맞춤형 암 치료에 대한 관심 증가 등이 있습니다. 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 리툭시맙, 트라스투주맙, 베바시주맙의 바이오시밀러 채택 증가, 암 치료에서 면역조절제 및 조혈제 사용 확대, 호중구감소증 관리를 위한 g-CSF 바이오시밀러의 성장, 암 바이오시밀러의 병원 및 소매 약국 채널 확대, 비용 대비 효과적이고 접근성이 높은 비용 대비 효과적이고 접근성이 높은 암 치료 옵션에 대한 관심 증가 등이 있습니다.
암 치료에 사용되는 생물학적 제제의 특허 만료는 새로운 종양학 바이오시밀러의 개발을 촉진하고 있습니다. 생물학적 제제는 일정 기간 특허로 보호되며, 특허가 만료되면 바이오시밀러 대체품 개발이 가능해집니다. 생물학적 제제는 면역체계를 자극하여 암세포와 싸우도록 설계된 생물 유래 표적치료제입니다. 바이오시밀러는 생물학적 제제와 매우 유사하지만 완전한 복제는 아니며, 저렴한 비용으로 동등한 효과를 제공합니다. 예를 들어, 제약 및 생명공학 산업 전문 중국 기업 DrugTimes에 따르면, 2024년 2월 기준 2037년까지 25개 이상의 제품 특허 보호가 만료될 것으로 예상되며, 2024년 매출액을 기준으로 계산하면 총 2,364억 달러 이상의 매출 감소가 발생할 수 있다고 합니다. 특허 만료가 증가함에 따라 신규 종양 바이오시밀러 개발 수요가 증가할 것으로 예상되며, 이는 종양 바이오시밀러 시장의 성장을 가속할 것으로 전망됩니다.
암 바이오시밀러 시장을 선도하는 주요 기업들은 치료 효과 향상, 환자 결과 개선, 암 치료에 대한 전반적인 접근성 향상을 목표로 표적 생물학적 제제 및 단일 클론 항체를 포함한 첨단 암 치료제 개발에 집중하고 있습니다. 단일클론항체(mAbs)는 암세포의 특정 항원을 식별하고 결합하도록 설계된 실험실 개발 단백질로, 정밀한 표적화 및 면역 유도형 파괴를 가능하게 합니다. 예를 들어, 2023년 3월 미국 제약사 화이자가 시젠과 합병하여 430억 달러를 투자하여 암 치료제 포트폴리오를 강화했습니다. 화이자는 이러한 전략적 노력을 통해 암 치료 분야에서 입지를 강화하고, 첨단 암 치료법 개발을 가속화하며, 세계 주요 사망 원인 중 하나인 암에 대응하고 있습니다. 또한, 이번 투자는 미충족 수요를 충족하고 암 치료에 대한 세계 접근성을 확대하기 위해 혁신적인 종양학 바이오시밀러에 대한 대규모 자본 투입이 증가하고 있는 추세를 잘 보여줍니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Oncology biosimilars are biologically similar drugs that closely resemble existing biologic cancer therapies in terms of safety, purity, and effectiveness. They are used to manage treatment-related effects such as reduced white blood cell counts, which increase the risk of infection during cancer therapy.
The primary drug types of oncology biosimilars include monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that mainly target immune pathways involved in the treatment of multiple myeloma and certain other cancers. These biosimilars are used to treat cancers such as breast cancer, colorectal cancer, blood cancer, neutropenia-related conditions, and non-small cell lung cancer, and they are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
Tariffs have impacted the oncology biosimilars market by raising costs of imported biologics, monoclonal antibodies, and active pharmaceutical ingredients. Hospital and retail pharmacy channels in regions such as North America and Europe, which rely on imports, are most affected. This has increased treatment costs and slowed market growth in short term. On the positive side, tariffs have encouraged local production, domestic R&D investments, and innovation in cost-effective biosimilar therapies, improving long-term access and affordability.
The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides oncology biosimilars market statistics, including oncology biosimilars industry global market size, regional shares, competitors with a oncology biosimilars market share, detailed oncology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. This oncology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The oncology biosimilars market size has grown rapidly in recent years. It will grow from $11.35 billion in 2025 to $12.83 billion in 2026 at a compound annual growth rate (CAGR) of 13.0%. The growth in the historic period can be attributed to high cost of reference biologics, limited availability of oncology biosimilars, increasing cancer prevalence globally, growing hospital and pharmacy infrastructure, early regulatory approvals for monoclonal antibody biosimilars.
The oncology biosimilars market size is expected to see rapid growth in the next few years. It will grow to $21.28 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to launch of new biosimilar drugs including pembrolizumab and pegfilgrastim, expansion of online pharmacy distribution channels, rising adoption of immunomodulators and hematopoietic agents, increasing government initiatives to improve cancer care access, growing focus on personalized oncology treatment. Major trends in the forecast period include rising adoption of rituximab, trastuzumab, and bevacizumab biosimilars, increasing use of immunomodulators and hematopoietic agents in cancer therapy, growth in g-csf biosimilars for neutropenia management, expansion of hospital and retail pharmacy channels for oncology biosimilars, focus on cost-effective and accessible cancer treatment options.
The expiration of patents for biologics used in cancer treatment is encouraging the development of new oncology biosimilars. Biologics are protected by patents for a limited duration, and once these patents expire, it becomes possible to develop biosimilar alternatives. Biologics are targeted therapies derived from living organisms that stimulate the immune system to fight cancer cells. Biosimilars closely resemble biologics but are not exact replicas, offering comparable effectiveness at a lower cost. For example, in February 2024, according to DrugTimes, a China-based company focused on the pharmaceutical and biotechnology industry, more than 25 products are expected to lose patent protection by 2037, potentially leading to a combined revenue decline of over $236.4 billion based on 2024 sales figures. The rising number of patent expirations is anticipated to increase demand for the development of new oncology biosimilars, thereby driving growth in the oncology biosimilars market.
Leading companies in the oncology biosimilars market are concentrating on the development of advanced cancer therapies, including targeted biologics and monoclonal antibodies, to improve treatment effectiveness, patient outcomes, and overall accessibility in oncology care. Monoclonal antibodies (mAbs) are laboratory-developed proteins designed to identify and bind to specific antigens on cancer cells, allowing precise targeting and immune-driven destruction. For instance, in March 2023, Pfizer, a US-based pharmaceutical company, merged with Seagen and invested $43 billion to strengthen its oncology portfolio. This strategic initiative enhances Pfizer's position in cancer therapeutics and accelerates the development of advanced cancer treatments, addressing one of the leading causes of death globally. The investment also highlights the growing trend of substantial capital deployment toward innovative oncology biosimilars to meet unmet medical needs and expand global access to cancer care.
In October 2024, Teva Pharmaceuticals Inc., an Israel-based pharmaceutical company, entered into a partnership with mAbxience to advance next-generation oncology biosimilar solutions. This collaboration focuses on expanding access to and advancing the development of high-quality oncology biosimilars, with the goal of improving patient outcomes in cancer treatment while supporting innovation and growth within the oncology biologics market. mAbxience S.A. is a Spain-based biopharmaceutical company specializing in the development and commercialization of monoclonal antibody biosimilars.
Major companies operating in the oncology biosimilars market are Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Viatris Inc., Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech
North America was the largest region in the global oncology biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Oncology Biosimilars Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses oncology biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for oncology biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oncology biosimilars market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Type: Monoclonal Antibody; Immunomodulators; Hematopoietic Agents; Granulocyte Colony-Stimulating Factor (G-CSF)
2) By Cancer Type: Breast Cancer; Colorectal Cancer; Blood Cancer; Neutropenia Cancer; Non-Small Cell Lung Cancer; Other Cancer Types
3) By Distribution Type: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Rising Adoption Of Rituximab, Trastuzumab, And Bevacizumab Biosimilars
4.2.2 Increasing Use Of Immunomodulators And Hematopoietic Agents In Cancer Therapy
4.2.3 Growth In G-Csf Biosimilars For Neutropenia Management
4.2.4 Expansion Of Hospital And Retail Pharmacy Channels For Oncology Biosimilars
4.2.5 Focus On Cost-Effective And Accessible Cancer Treatment Options
5. Oncology Biosimilars Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Retail Pharmacies
5.3 Online Pharmacies
5.4 Cancer Treatment Centers
5.5 Contract Research Organizations (Cros)
6. Oncology Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Oncology Biosimilars Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Oncology Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Oncology Biosimilars Market Size, Comparisons And Growth Rate Analysis
7.3. Global Oncology Biosimilars Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Oncology Biosimilars Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Oncology Biosimilars Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Oncology Biosimilars Market Segmentation
9.1. Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.4. Global Oncology Biosimilars Market, Sub-Segmentation Of Monoclonal Antibody, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.6. Global Oncology Biosimilars Market, Sub-Segmentation Of Hematopoietic Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Epoetin Biosimilars, Darbepoetin Biosimilars
9.7. Global Oncology Biosimilars Market, Sub-Segmentation Of Granulocyte Colony-Stimulating Factor (G-CSF), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Filgrastim Biosimilars, Pegfilgrastim Biosimilars
10. Oncology Biosimilars Market Regional And Country Analysis
10.1. Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Oncology Biosimilars Market
12.1. China Oncology Biosimilars Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Oncology Biosimilars Market
13.1. India Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Oncology Biosimilars Market
14.1. Japan Oncology Biosimilars Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Oncology Biosimilars Market
15.1. Australia Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Oncology Biosimilars Market
16.1. Indonesia Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Oncology Biosimilars Market
17.1. South Korea Oncology Biosimilars Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Oncology Biosimilars Market
18.1. Taiwan Oncology Biosimilars Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Oncology Biosimilars Market
19.1. South East Asia Oncology Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Oncology Biosimilars Market
20.1. Western Europe Oncology Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Oncology Biosimilars Market
21.1. UK Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Oncology Biosimilars Market
22.1. Germany Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Oncology Biosimilars Market
23.1. France Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Oncology Biosimilars Market
24.1. Italy Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Oncology Biosimilars Market
25.1. Spain Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Oncology Biosimilars Market
26.1. Eastern Europe Oncology Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Oncology Biosimilars Market
27.1. Russia Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Oncology Biosimilars Market
28.1. North America Oncology Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Oncology Biosimilars Market
29.1. USA Oncology Biosimilars Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Oncology Biosimilars Market
30.1. Canada Oncology Biosimilars Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Oncology Biosimilars Market
31.1. South America Oncology Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Oncology Biosimilars Market
32.1. Brazil Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Oncology Biosimilars Market
33.1. Middle East Oncology Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Oncology Biosimilars Market
34.1. Africa Oncology Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Oncology Biosimilars Market Regulatory and Investment Landscape
36. Oncology Biosimilars Market Competitive Landscape And Company Profiles
36.1. Oncology Biosimilars Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Oncology Biosimilars Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Oncology Biosimilars Market Company Profiles
36.3.1. Biocon Biologics Limited Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Celltrion Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
36.3.5. STADA Arzneimittel AG Overview, Products and Services, Strategy and Financial Analysis
37. Oncology Biosimilars Market Other Major And Innovative Companies
Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG
38. Global Oncology Biosimilars Market Competitive Benchmarking And Dashboard
39. Key Mergers And Acquisitions In The Oncology Biosimilars Market
40. Oncology Biosimilars Market High Potential Countries, Segments and Strategies
40.1 Oncology Biosimilars Market In 2030 - Countries Offering Most New Opportunities
40.2 Oncology Biosimilars Market In 2030 - Segments Offering Most New Opportunities
40.3 Oncology Biosimilars Market In 2030 - Growth Strategies
